HomeCompareCHJTF vs CHD

CHJTF vs CHD: Dividend Comparison 2026

CHJTF yields 3.02% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHJTF wins by $44.87M in total portfolio value
10 years
CHJTF
CHJTF
● Live price
3.02%
Share price
$1.02
Annual div
$0.03
5Y div CAGR
87.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.89M
Annual income
$39,983,177.94
Full CHJTF calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — CHJTF vs CHD

📍 CHJTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCHJTFCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CHJTF + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CHJTF pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CHJTF
Annual income on $10K today (after 15% tax)
$256.35/yr
After 10yr DRIP, annual income (after tax)
$33,985,701.25/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, CHJTF beats the other by $33,984,602.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CHJTF + CHD for your $10,000?

CHJTF: 50%CHD: 50%
100% CHD50/50100% CHJTF
Portfolio after 10yr
$22.46M
Annual income
$19,992,235.22/yr
Blended yield
89.02%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

CHJTF
No analyst data
Altman Z
5.9
Piotroski
5/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CHJTF buys
0
CHD buys
0
No recent congressional trades found for CHJTF or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCHJTFCHD
Forward yield3.02%1.27%
Annual dividend / share$0.03$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR87.3%23.1%
Portfolio after 10y$44.89M$26.4K
Annual income after 10y$39,983,177.94$1,292.51
Total dividends collected$44.48M$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: CHJTF vs CHD ($10,000, DRIP)

YearCHJTF PortfolioCHJTF Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$11,265$564.87$10,856$156.32+$409.00CHJTF
2$13,167$1,113.86$11,811$195.24+$1.4KCHJTF
3$16,368$2,279.06$12,883$244.38+$3.5KCHJTF
4$22,473$4,959.20$14,091$306.64+$8.4KCHJTF
5$35,965$11,918.72$15,463$385.88+$20.5KCHJTF
6$71,871$33,388.76$17,033$487.17+$54.8KCHJTF
7$193,699$116,796.73$18,843$617.36+$174.9KCHJTF
8$758,265$551,007.12$20,947$785.72+$737.3KCHJTF
9$4,587,110$3,775,766.40$23,419$1,004.91+$4.56MCHJTF
10$44,891,385$39,983,177.94$26,350$1,292.51+$44.87MCHJTF

CHJTF vs CHD: Complete Analysis 2026

CHJTFStock

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full CHJTF Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this CHJTF vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CHJTF vs SCHDCHJTF vs JEPICHJTF vs OCHJTF vs KOCHJTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.